Jonathan Chang analyst LEERINK

Currently out of the existing stock ratings of Jonathan Chang, 74 are a BUY (63.79%), 42 are a HOLD (36.21%).

Jonathan Chang

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Chang works at LEERINK with a stock forecast success ratio of 50.61% fulfilled within 254.37 days on average.

Jonathan Chang’s has documented 197 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 10-Jan-2023.

Wall Street Analyst Jonathan Chang

Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for IMGN (IMMUNOGEN) at 11/30/2021. The price target of $7 was fulfilled within 2 days with a profit of $0.83 (13.45%) receiving and performance score of 67.26.

Average potential price target upside

ADAP Adaptimmune Therapeutics Plc CALA Calithera Biosciences IMGN ImmunoGen IMTX Immatics NV KPTI Karyopharm Therapeutics MGNX MacroGenics ZLAB Zai Lab Ltd BCYC Bicycle Therapeutics Ltd GMAB Genmab AS HARP Harpoon Therapeutics KURA Kura Oncology REPL Replimune Group RVMD Revolution Medicines ATNX Athenex RUBY Rubius Therapeutics TCRR Tcr2 Therapeutics VINC Vincerx Pharma MRSN Mersana Therapeutics XNCR Xencor

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

1

$-0.05 (-4.76%)

4

9 months 16 days ago

3/4 (75%)

$0.18 (21.95%)

245

Buy

5

$3.95 (376.19%)

1 years 4 months 23 days ago

0/2 (0%)

$3.33 (199.40%)

Buy

9

$8.22 (1053.85%)

9

1 years 6 months 17 days ago

2/3 (66.67%)

$1.29 (98.13%)

340

Hold

3

$1.95 (185.71%)

2 years 17 days ago

1/5 (20%)

$1.46 (94.81%)

377

Buy

6

$5.22 (669.23%)

16

5 years 19 days ago

1/3 (33.33%)

$6.36 (92.59%)

388

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Jonathan Chang?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?